血清神经丝轻链和胶质纤维酸性蛋白水平与那他珠单抗治疗多发性硬化症患者的停药症状无关。
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
机构信息
Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
出版信息
Mult Scler. 2024 Nov;30(13):1683-1688. doi: 10.1177/13524585241293940. Epub 2024 Nov 4.
BACKGROUND
Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs).
OBJECTIVES
We investigated the longitudinal association between and predictive value of sNfL and sGFAP and the occurrence of WoS in MS patients treated with natalizumab.
METHODS
We performed longitudinal measurements of sNfL and sGFAP in NEXT-MS trial participants who completed a questionnaire about WoS.
RESULTS
A total of 364 participants were included. In total, 55.5% presented with WoS and 44.5% without WoS during natalizumab treatment. Longitudinal analyses showed no association between sNfL and sGFAP levels and WoS at any timepoint. Biomarker levels at baseline did not predict first-time WoS occurrence.
CONCLUSION
Acute and chronic neuronal and axonal damage are most likely not the underlying cause of WoS.
背景
神经元和轴突损伤的生物标志物（血清神经丝轻链（sNfL）和血清神经胶质纤维酸性蛋白（sGFAP））可能有助于了解那他珠单抗失效症状（WoSs）的病因。
目的
我们研究了血清 NfL 和 sGFAP 与 MS 患者接受那他珠单抗治疗时发生 WoS 的纵向关联及其预测价值。
方法
我们对 NEXT-MS 试验参与者进行了血清 NfL 和 sGFAP 的纵向测量，这些参与者完成了一份关于 WoS 的问卷。
结果
共纳入 364 名参与者。在那他珠单抗治疗期间，共有 55.5%的患者出现 WoS，44.5%的患者无 WoS。纵向分析显示，在任何时间点，sNfL 和 sGFAP 水平与 WoS 之间均无关联。基线时的生物标志物水平不能预测首次出现 WoS。
结论
急性和慢性神经元和轴突损伤极不可能是 WoS 的根本原因。
Zotero 插件